What is the appropriate evaluation and management of clonus in a patient with multiple sclerosis?

Management of Clonus in Multiple Sclerosis

Clonus in MS patients is a manifestation of upper motor neuron spasticity and should be treated with a stepwise approach beginning with physical therapy, followed by oral baclofen (30–80 mg/day in divided doses), and escalating to intrathecal baclofen for refractory cases. 1

Understanding Clonus in the Context of MS

Clonus represents involuntary, rhythmic muscle contractions (typically 5-8 Hz frequency) caused by hyperactive stretch reflexes from upper motor neuron lesions in the descending motor pathways. 2 In MS, this occurs due to demyelination and axonal injury affecting corticospinal tracts. The mechanism involves peripheral self-excitation rather than a central spinal pacemaker, as demonstrated by the inverse relationship between reflex path length and clonus frequency. 3

Clinical Evaluation

• Test for velocity-dependence during passive joint movement to confirm spasticity rather than rigidity—rapid passive stretching will aggravate clonus while slow movement alleviates it. 1
• Look for the "clasp-knife" phenomenon where resistance suddenly releases during passive stretch, which distinguishes spasticity from the velocity-independent "lead-pipe" rigidity of parkinsonian disorders. 1
• Assess functional impact on activities of daily living, positioning, and whether painful muscle spasms are interfering with rehabilitation. 1

Common Pitfall to Avoid

Misidentifying spasticity as rigidity leads to inappropriate dopaminergic therapy instead of antispasticity agents—always prioritize velocity-dependence testing to ensure correct treatment selection. 1

Treatment Algorithm

First-Line: Non-Pharmacologic Interventions

• Initiate stretching exercises, range-of-motion activities, proper positioning, and splinting as the foundation of management before considering medications. 1
• These physical modalities should be maintained throughout treatment regardless of pharmacologic escalation. 1

Second-Line: Oral Pharmacotherapy for Generalized Spasticity

• Prescribe oral baclofen 30–80 mg/day divided into 3–4 doses as the primary pharmacologic agent for generalized spasticity with clonus. 1
• Baclofen has demonstrated statistically significant reduction in clonus frequency and spasm severity in MS patients, with optimal effect when administered early before major disabilities become permanent. 4
• Alternative oral agents include tizanidine or dantrolene if baclofen is not tolerated, though baclofen remains the evidence-based first choice. 1

Focal Spasticity Alternative

• For isolated focal clonus affecting specific muscle groups, botulinum toxin injections are preferred over systemic oral agents. 1
• Cold application and phenol injections represent additional focal treatment options. 2

Third-Line: Refractory Cases

• Intrathecal baclofen therapy is indicated for severe clonus and spasticity unresponsive to maximum oral doses. 1
• Emerging evidence suggests percutaneous epidural spinal cord stimulation can immediately terminate mechanically evoked clonus, though this remains investigational. 5

Long-Term Monitoring

• Baclofen demonstrates no toxic effects on hepatologic, hematopoietic, or renal function even with over 3 years of continuous use, making it safe for chronic management. 4
• Regular assessment of functional status and range of joint movement helps determine treatment efficacy beyond just clonus reduction. 4